Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Company Overview

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key Stats

• Today's Range: $2.58 to $2.81
• 50-Day Range: $2.54 to $4.73
• 52-Week Range: $2.37 to $9.40
• Volume: 22,752 shs
• Average Volume: 262,845 shs
• Market Capitalization: $3.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KTTA Stock Analysis - Frequently Asked Questions

How have KTTA shares performed this year?

Pasithea Therapeutics' stock was trading at $7.40 at the beginning of the year. Since then, KTTA shares have decreased by 64.5% and is now trading at $2.63.
View the best growth stocks for 2024 here.

When did Pasithea Therapeutics' stock split?

Pasithea Therapeutics's stock reverse split on Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Pasithea Therapeutics IPO?

Pasithea Therapeutics (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pasithea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KTTA
• CUSIP: N/A
• CIK: 1841330
• Web: www.pasithea.com
• Phone: 702-514-4174
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-15,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.57%
• Return on Assets: -74.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.82
• Quick Ratio: 14.82

Sales & Book Value

• Annual Sales: $20,000.00
• Price / Sales: 166.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $22.46 per share
• Price / Book: 0.12

Miscellaneous

• Outstanding Shares: 1,266,000
• Free Float: 1,060,000
• Market Cap: $3.33 million
• Optionable: Not Optionable
• Beta: 0.73